Sanofi

News

Maze gets new Pompe partner after FTC blocks Sanofi deal

Five months after Sanofi backed away from a proposed deal with Maze Therapeutics on a Pompe disease therapy after an antitrust challenge, Shionogi has snapped up the drug.

News

Sanofi forges $1.2bn alliance with vaccines firm Novavax

Sanofi has licensed joint commercial rights to Novavax’s COVID-19 vaccine and will work with the biotech on the development of combined flu/COVID shots in a deal worth up

News

Sanofi’s oral BTK programme gets back on track

Sanofi has chalked up another win in a clinical trial of its oral BTK inhibitor rilzabrutinib, setting up regulatory filings in its first indication – rare disorder immune

News

EMA finds no suicide risk with GLP-1 diabetes, obesity drugs

There is no evidence of an increased risk of suicidal or self-injurious thoughts and actions with GLP-1 agonists used to treat diabetes and obesity, according to the EU me

News

Trial finds benefit for GLP-1 agonist in Parkinson’s

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for t

News

AAD: Sanofi showcases data on possible Dupixent successor

Sanofi says that its experimental drug amlitelimab has the potential to become a ‘best-in-class’ maintenance therapy for atopic dermatitis (AD) after reporting new phase 2

Maze gets new Pompe partner after FTC blocks Sanofi deal

Sanofi forges $1.2bn alliance with vaccines firm Novavax

Sanofi’s oral BTK programme gets back on track

EMA finds no suicide risk with GLP-1 diabetes, obesity drugs

Trial finds benefit for GLP-1 agonist in Parkinson’s

AAD: Sanofi showcases data on possible Dupixent successor

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Sanofi

Editor's Picks